The Opioid Multidistrict Litigation, Federal Rule 23, and the Negotiation Class
A recent Sixth Circuit decision dashed hopes of a faster resolution to the federal opioid multidistrict litigation (MDL).
Class Action
-
Read more: The Opioid Multidistrict Litigation, Federal Rule 23, and the Negotiation Class -
Read more: Violations of federal antifraud provisions alleged against two hepatitis B treatment producers Violations of federal antifraud provisions alleged against two hepatitis B treatment producers
By Wendy S. Salkin Two investor class-action suits have been filed within days of one another against two different California-based pharmaceutical companies both of which produce hepatitis B treatments, Dynavax Technologies and Arrowhead Pharmaceuticals. The named plaintiffs in both shareholder class-action suits, David Soontjens and Yaki J. Meller, are represented by counsel at Pomerantz, LLP.[1] Meller…